The context and potential of epigenetics in oncology

Cancer has long been known to be a disease caused by alterations in the genetic blueprint of cells. In the past decade it has become evident that epigenetic processes have a function, at least equally important, in neoplasia. Epigenetics describes the mechanisms that result in heritable alterations in gene expression profiles without an accompanying change in DNA sequence. Genetics and epigenetics intricately interact in the pathogenesis of cancer (Esteller, 2007). In this review, we paint a broad picture of current understanding of epigenetic changes in cancer cells and reflect on the immense clinical potential of emerging knowledge of epigenetics in the diagnosis, prognostic assessment, treatment, and screening of cancer.

[1]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Glasspool,et al.  Epigenetics as a mechanism driving polygenic clinical drug resistance , 2006, British Journal of Cancer.

[3]  J. Herman,et al.  Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  W. Leung,et al.  Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  M. Fraga,et al.  Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. , 2006, Cancer research.

[6]  M. Esteller.  Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[7]  A. Nakao,et al.  Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[9]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[10]  Matthew Tudor,et al.  Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation , 2001, Nature Genetics.

[11]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[12]  F. Gilliland,et al.  Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. , 2002, Cancer research.

[13]  R. Durbin,et al.  A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis , 2008, Nature Biotechnology.

[14]  W. Schulz,et al.  Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma. , 1996, Cancer research.

[15]  Bela Molnar,et al.  DNA methylation biomarkers for blood-based colorectal cancer screening. , 2008, Clinical chemistry.

[16]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[17]  A. Mazumder,et al.  Development of a multiplexed urine assay for prostate cancer diagnosis. , 2008, Clinical chemistry.

[18]  J. Sludden,et al.  Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.

[19]  M. Widschwendter,et al.  DNA Methylation in Serum and Tumors of Cervical Cancer Patients , 2004, Clinical Cancer Research.

[20]  K. Miller,et al.  Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. , 2000, Cancer research.

[21]  Peter A. Jones,et al.  Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. , 2006, Cancer cell.

[22]  P. Laird,et al.  Epigenetic stem cell signature in cancer , 2007, Nature Genetics.

[23]  J. Schouten,et al.  Sequential gene promoter methylation during HPV-induced cervical carcinogenesis , 2007, British Journal of Cancer.

[24]  G. Patrinos,et al.  DNA hypermethylation: when tumour suppressor genes go silent , 2002, Human Genetics.

[25]  R J C Steele,et al.  Relationship between point gene mutation, chromosomal abnormality, and tumour suppressor gene methylation status in colorectal adenomas , 2006, The Journal of pathology.

[26]  Ola Snøve,et al.  Epigenetics and MicroRNAs , 2007, Pediatric Research.

[27]  D. Aoki,et al.  Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. , 2006, Oncology reports.

[28]  A. Feinberg,et al.  Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk , 2003, Science.

[29]  Zohar Yakhini,et al.  Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer , 2007, Nature Genetics.

[30]  Chih-Yi Chen,et al.  Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. , 2003, The Journal of clinical investigation.

[31]  G. Strathdee,et al.  A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer , 1999, Oncogene.

[32]  E. Brambilla,et al.  Tumor-Specific Methylation in Saliva: A Promising Biomarker for Early Detection of Head and Neck Cancer Recurrence , 2007, Clinical Cancer Research.

[33]  A. Balmain,et al.  A Mouse Skin Multistage Carcinogenesis Model Reflects the Aberrant DNA Methylation Patterns of Human Tumors , 2004, Cancer Research.

[34]  J. Herman,et al.  DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. , 2001, Human molecular genetics.

[35]  Debra Silverman,et al.  Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. , 2008, The Lancet. Oncology.

[36]  S. Berger.  The complex language of chromatin regulation during transcription , 2007, Nature.

[37]  Andreas Schätzlein,et al.  Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Herman,et al.  A Gene Hypermethylation Profile of Human Cancer 1 , 2001 .

[39]  Frank Diehl,et al.  Detection and quantification of mutations in the plasma of patients with colorectal tumors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. O’Day,et al.  Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  T. Visakorpi,et al.  Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma , 2002, Genes, chromosomes & cancer.

[42]  H. Brenner,et al.  Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A Proof of Principle Study , 2008, PloS one.

[43]  P. Marks,et al.  Histone deacetylase inhibitors: molecular mechanisms of action , 2007, Oncogene.

[44]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[45]  Robert Brown,et al.  The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients , 2004, Clinical Cancer Research.

[46]  P. Guldberg,et al.  Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patients , 2006, European journal of haematology.

[47]  K. He,et al.  Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma , 2007, Clinical Cancer Research.

[48]  M. Widschwendter,et al.  Methylation changes in faecal DNA: a marker for colorectal cancer screening? , 2004, The Lancet.

[49]  Kelly M. McGarvey,et al.  A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing , 2007, Nature Genetics.

[50]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[51]  S. Minucci,et al.  Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor , 2002, Science.

[52]  Peter A. Jones,et al.  Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. , 2002, Blood.

[53]  J. Herman,et al.  Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. , 2000, Cancer research.

[54]  Steven S. Chang,et al.  Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma , 2008, Clinical Cancer Research.

[55]  P. Laird,et al.  Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. , 2003, Lung cancer.

[56]  J. Herman,et al.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[57]  L. Myeroff,et al.  Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. , 2005, Journal of the National Cancer Institute.

[58]  M. Fraga,et al.  Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. , 2007, Neoplasia.

[59]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[60]  J. Califano,et al.  Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer , 2004, Cancer Research.